51175-71-4

Usage

Uses

Used in Pharmaceutical Industry:
3-Thiophenesulfonyl chloride is used as a synthetic building block for the development of pharmaceutical compounds. Its ability to introduce functional groups into organic molecules aids in the creation of new drug candidates with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 3-Thiophenesulfonyl chloride is utilized as a reagent for the synthesis of agrochemicals. Its strong electrophilic nature facilitates the introduction of sulfonyl chloride moieties into organic molecules, enhancing their pesticidal or herbicidal properties.
Used in Organic Synthesis:
3-Thiophenesulfonyl chloride is employed as a versatile reagent in organic synthesis for its capacity to participate in various chemical reactions. This includes nucleophilic substitution, oxidation, and radical reactions, which are essential for the formation of complex organic structures.
Used in Dye Synthesis:
3-THIOPHENESULFONYL CHLORIDE is also used as a precursor in the synthesis of dyes, where its ability to introduce functional groups can alter the color and properties of the resulting dyes, expanding their applications in various industries.
Used in Heterocyclic Compound Synthesis:
3-Thiophenesulfonyl chloride is utilized in the synthesis of heterocyclic compounds, which are important in various fields such as medicinal chemistry, materials science, and organic synthesis. Its role in introducing sulfonyl chloride groups can significantly influence the reactivity and properties of these heterocyclic systems.

InChI:InChI=1/C4H3ClO2S2/c5-9(6,7)4-1-2-8-3-4/h1-3H

Upstream product

• 858840-32-1 5-iodo-thiophene-2,4-disulfonyl chloride 
• 872-31-1 3-Bromothiophene 
• 6165-69-1 Thien-3-ylboronic acid 

Downstream Products

• 111711-67-2 5-ethoxy-1-[(3-thienyl)-sulphonyl]-2-pyrrolidinone 
• 852063-92-4 thiophene-3-sulfonic acid 7-cyano-2,3-diphenyl-indolizin-1-yl ester 
• 33084-49-0 4-bromo-3-methyl-5-aminoisoxazole 
• 1138036-32-4 2-(2-fluorophenyl)-1-(thiophen-3-ylsulfonyl)-1H-imidazole-4-carbaldehyde 
• 1229097-02-2 N-[4-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(trifluoromethyl)-phenyl]-3-thiophenesulfonamide 
• 1447963-70-3 N-cyclohexylthiophene-3-sulfonamide 
• 16718-05-1 3-(phenylsulfonyl)thiophene 
• 1380228-94-3 N-(2,4-difluoro-3-(3-(9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-yl)pyridin-2-ylamino)phenyl)thiophene-3-sulfonamide 

Relevant academic research and scientific papers

Synthesis of aryl sulfonamides via palladium-catalyzed chlorosulfonylation of arylboronic acids

A palladium-catalyzed method for the preparation of sulfonamides is described. The process exhibits significant functional group tolerance and allows for the preparation of a number of arylsulfonyl chlorides and sulfonamides under mild conditions.

Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin

Biphenylsulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, bicyclic or tricyclic carbon or heterocyclic ring biphenylsulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.

N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin

Thienyl-, furyl- and pyrrolyl-sulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides and N-(isoxazolyl)pyrrolylsulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.

THIENYL-, FURYL- AND PYRROLYL SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN

Thienyl-, furyl-and pyrrolyl-sulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl) furylsulfonamides and N-(isoxazolyl)pyrrolylsulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.

Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin

Thiophenyl-, furyl- and pyrrolyl-sulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, isoxazolyl-thiophenyl-sulfonamides, isoxazolyl-furyl-sulfonamides and isoxazolyl-pyrrolyl-sulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.

Thiophenesulfonamides as endothelin receptor antagonists

The synthesis and in vitro binding affinities of a series of thiophenesulfonamides as ET(A) selective endothelin receptor antagonists is described. The most potent inhibitor displayed an IC50 of 43 nM and 3 μM to ET(A) and ET(B) receptors, respectively.

SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN

Sulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided. The sulfonamides have formula I: STR1 in which Ar 1 is a 3-or 5-isoxazolyl and Ar. sup.2 is selected from among alkyl, including straight and branched chains, aromatic rings, fused aromatic rings and heterocyclic rings, including 5-membered heterocycles with one, two or more heteroatoms and fused ring analogs thereof and 6-membered rings with one, two or more heteroatoms and fused ring analogs thereof. Ar 2 is preferably thiophenyl, furyl, pyrrolyl, naphthyl, and phenyl. Compounds in which Ar. sup.1 is a 4-halo-substituted isoxazole are more active than the corresponding alkyl-substituted compound and compounds in which Ar 1 is substituted at this position with a higher alkyl tend to exhibit greater affinity for ET B receptors than the corresponding lower alkyl-substituted compound.